GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

NCT06630585 on ClinicalTrials.gov · last registry update 2026-01-26

A small phase 3 — 42 participants, against a typical 424. Its estimated completion date, June 2026, has passed with no update to the record. Primary outcome, as filed: Change TIR. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. tirzepatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: University of Bern
Sponsor type: Other
Enrollment: 42
Started: 2025-02-14
Primary completion: 2026-06 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change TIR

Conditions studied

Type 1 Diabetes (T1D)

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.